-
Bayern held at Hamburg to open door for Dortmund
-
Atletico stumble to draw at Levante, Villarreal held
-
Chelsea stage impressive fightback to beat West Ham
-
Arsenal stretch Premier League lead, Chelsea fightback breaks Hammers' hearts
-
Napoli edge Fiorentina as injury crisis deepens
-
How Lego got swept up in US-Mexico trade frictions
-
UK rights campaigner Tatchell arrested at pro-Palestinian protest
-
Iran says progress made towards US talks despite attack jitters
-
'Empowering': Ireland's first female sumo wrestler blazes a trail
-
US judge denies Minnesota bid to suspend immigration sweeps
-
Ukraine hit by mass power outages after 'technical malfunction'
-
AC Milan prolong France 'keeper Maignan deal by five years
-
Arteta hails Arsenal's statement rout of Leeds
-
Marseille buckle as Paris FC battle back for draw
-
Protesters demand 'justice' one month after Swiss bar fire
-
Philadelphia's Paul George gets 25-game NBA drugs ban
-
La Rochelle suffer defeat after shock Atonio retirement
-
'It wasn't working': Canada province ends drug decriminalization
-
Kishan, Arshdeep star as India down New Zealand in T20 finale
-
Moreno bags brace but Villarreal held at Osasuna
-
Kramaric keeps in-form Hoffenheim rolling in Bundesliga
-
'Skimo': Adrenalin-packed sprint to make Olympic debut
-
Venezuela's 'Helicoide' prison synonymous with torture of dissenters
-
Arsenal thrash Leeds to stretch Premier League advantage
-
Russia's Valieva returns to ice after doping ban
-
Snow storm barrels into southern US as blast of icy weather widens
-
Ukraine sees mass power outages from 'technical malfunction'
-
Gaza civil defence says Israeli strikes kill 32
-
Kirsty Coventry set to give clues to her Olympic vision in Milan
-
I'm no angel, Italy's PM says amid church fresco row
-
Thousands join Danish war vets' silent march after Trump 'insult'
-
Gaza civil defence says Israeli strikes kill 28
-
Pakistan spin out Australia in second T20I to take series
-
Melbourne champion Rybakina never doubted return to Wimbledon form
-
Luis Enrique welcomes Ligue 1 challenge from Lens
-
Long truck lines at Colombia-Ecuador border as tariffs loom
-
Ex-prince Andrew dogged again by Epstein scandal
-
Separatist attacks in Pakistan kill 21, dozens of militants dead
-
'Malfunction' cuts power in Ukraine. Here's what we know
-
Arbeloa backs five Real Madrid stars he 'always' wants playing
-
Sabalenka 'really upset' at blowing chances in Melbourne final loss
-
Britain, Japan agree to deepen defence and security cooperation
-
Rybakina keeps her cool to beat Sabalenka in tense Melbourne final
-
France tightens infant formula rules after toxin scare
-
Blanc wins final women's race before Winter Olympics
-
Elena Rybakina: Kazakhstan's Moscow-born Melbourne champion
-
Ice-cool Rybakina beats Sabalenka in tense Australian Open final
-
Pakistan attacks kill 15, dozens of militants dead: official
-
Ten security officials, 37 militants killed in SW Pakistan attacks: official
-
Epstein survivors say abusers 'remain hidden' after latest files release
US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
D.Johnson--AT